Questionable Sales Practices in the Drug Industry: Hearing Before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, Second Session, Washington, DC, October 12, 1994, Volume 4
United States, United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Technology
U.S. Government Printing Office, 1995 - Advertising - 213 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
abuses acromegaly activities addition agency approved associated believe benefit Brown Business Caremark cause Chairman WYDEN child clinical concern conduct continue costs criminal decision Department discuss disease distribution doctors drug companies effects evaluation expensive fact Federal Foundation fraud funds Genentech going grants growing growth hormone deficiency health care height human growth hormone hypothyroidism important increase indicated industry interest involved issues kickbacks kind letter Lilly managed marketing materials measurements Medicaid never normal offered opportunity organizations parents patients pediatric pediatric endocrinologist pharmaceutical physicians potential practices prescribe prescription drug present problems programs promotional Protropin providers questions receive recommend referred regarding regulations Representatives response result risk scientific screening short specific sponsored statement stature subcommittee subjects tests Thank therapy treated treatment